SCHEMBL25027

SCHEMBL25027

CC(=O)Oc1ccc(Br)cc1C(=O)O

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFD P00746 2/20 0.73
KDM4E B2RXH2 7/20 0.61
HSD17B10 Q99714 5/20 0.61
ALDH1A1 P00352 5/20 0.61
TSHR P16473 3/20 0.61
HPGD P15428 3/20 0.61
PTGS1 P23219 2/20 0.61
PTGS2 P35354 2/20 0.61
ESR1 P03372 1/20 0.61
ITGB3 P05106 1/20 0.61
ITGA2B P08514 1/20 0.61
HMGB1 P09429 1/20 0.61
GGT1 P19440 1/20 0.61
BLM P54132 1/20 0.61
NAPRT Q6XQN6 1/20 0.61
TDP1 Q9NUW8 1/20 0.61
GAA P10253 1/20 0.55
RAB9A P51151 1/20 0.55
LMNA P02545 1/20 0.54
CYP1A2 P05177 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2761803 0.89 KDM4E (0.67) CFDKDM4EHSD17B10ALDH1A1TSHR
SCHEMBL789388 0.89 PTGDR2 (0.63) CFDKDM4EHSD17B10ALDH1A1TSHR
SCHEMBL3382142 0.85 CFD (0.54) CFDKDM4EHSD17B10ALDH1A1TSHR
SCHEMBL16715329 0.85 CFD (1.00) CFDKDM4EHSD17B10ALDH1A1TSHR
SCHEMBL3453790 0.84 TSHR (0.58) CFDKDM4EHSD17B10ALDH1A1TSHR
SCHEMBL1603859 0.84 HSD17B10 (0.58) CFDKDM4EHSD17B10ALDH1A1TSHR
SCHEMBL3284810 0.84 CFD (0.53) CFDKDM4EHSD17B10ALDH1A1TSHR
SCHEMBL344489 0.83 CFD (0.71) CFDKDM4EHSD17B10ALDH1A1TSHR
SCHEMBL344505 0.83 KDM4E (0.74) CFDKDM4EHSD17B10ALDH1A1TSHR
SCHEMBL1317371 0.83 CFD (0.71) CFDKDM4EHSD17B10ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2841066-B1 ANTI-INFLUENZA AGENT CONJUGATED TO ANTI-INFLAMMATORY AGENT ACADEMIA SINICA (TW) 2021-02-17 EP claimed
US-10758626-B2 Polymer conjugate comprising a bioactive agent POLYACTIVA PTY LTD (AU) 2020-09-01 US claimed
EP-3524272-A1 ENHANCED ANTI-INFLUENZA AGENTS CONJUGATED WITH ANTI-INFLAMMATORY ACTIVITY Academia Sinica (TW) 2019-08-14 EP claimed
US-20180303948-A1 POLYMER CONJUGATE COMPRISING A BIOACTIVE AGENT POLYACTIVA PTY LTD (AU) 2018-10-25 US claimed
EP-3347052-A1 POLYMER CONJUGATE COMPRISING A BIOACTIVE AGENT Polyactiva Pty Ltd (AU) 2018-07-18 EP claimed
US-9968684-B2 Polymer-NSAID conjugate POLYACTIVA PTY LTD (AU) 2018-05-15 US claimed
EP-2863921-B1 POLYMER-NSAID CONJUGATE POLYACTIVA PTY LTD (AU) 2018-04-18 EP claimed
WO-2017041142-A1 POLYMER CONJUGATE COMPRISING A BIOACTIVE AGENT POLYACTIVA PTY LTD (AU) 2017-03-16 WO claimed
US-20150328323-A1 Nitric Oxide Releasing Produgs of Therapeutic Agents SATYAM APPARAO (IN) 2015-11-19 US claimed
US-20150150999-A1 POLYMER-NSAID CONJUGATE POLYACTIVA PTY LTD (AU) 2015-06-04 US claimed
WO-2004005313-A2 HYBRID MOLECULES OF MACROLIDES WITH STEROID/NON-STEROID ANTI-INFLAMMATORY, ANTINEOPLASTIC AND ANTIVIRAL ACTIVE MOLECULES PLIVA - ISTRAZIVACKI INSTITUT D.O.O. (US) 2004-01-15 WO claimed
WO-2004005309-A2 NOVEL NONSTEROIDAL ANTI-INFLAMMATORY SUBSTANCES, COMPOSITIONS AND METHODS FOR THEIR USE PLIVA - ISTRAZIVACKI INSTITUT D.O.O. (US) 2004-01-15 WO claimed
US-20030235617-A1 Pharmaceutical dosage form for mucosal delivery MCNEIL-PPC, INC 2003-12-25 US claimed
US-20030180357-A1 Pharmaceutical tablet MCNEIL-PPC, INC 2003-09-25 US claimed
CN-1433396-A Pharmaceutical compounds NICOX SA (FR) 2003-07-30 CN claimed
EP-1324974-A2 DRUGS FOR DIABETES Nicox S.A. (FR) 2003-07-09 EP claimed
CN-1358178-A Pharmaceutical compounds NICOX SA (FR) 2002-07-10 CN claimed
CN-1354740-A Pharmaceutical compounds NICOX SA (FR) 2002-06-19 CN claimed
WO-2002030867-A2 DRUGS FOR DIABETES NICOX S.A. (FR) 2002-04-18 WO claimed
US-5985927-A Medicaments for the selective treatment of tumor tissues KREUTZ WERNER (DE) 1999-11-16 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030180357-A1 Pharmaceutical tablet GYPA, SORD, SRI CFD 1375/4885KDM4E 3204/4885HSD17B10 2700/4885
US-20150150999-A1 POLYMER-NSAID CONJUGATE PTGS1, PTGES3, PTGES CFD 2303/4885KDM4E 3166/4885HSD17B10 209/4885
US-10758626-B2 Polymer conjugate comprising a bioactive agent MSN, PAM, PARG CFD 2900/4885KDM4E 3935/4885HSD17B10 3174/4885
US-20180303948-A1 POLYMER CONJUGATE COMPRISING A BIOACTIVE AGENT MSN, PAM, PARG CFD 2900/4885KDM4E 3935/4885HSD17B10 3174/4885
US-20030235617-A1 Pharmaceutical dosage form for mucosal delivery SI, UGGT1, GYPA CFD 2954/4885KDM4E 2862/4885HSD17B10 1602/4885
US-20150328323-A1 Nitric Oxide Releasing Produgs of Therapeutic Agents NOS2, NOS1, PTGIS CFD 2417/4885KDM4E 3686/4885HSD17B10 1633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.